Zilia to Support Landmark Study on Retinal Degeneration and Regeneration
Quebec City, November 26, 2025 – Zilia, a health technology company at the forefront of oculomics, announced today that its platform, Zilia Ocular, will be used in a groundbreaking study at the Byers Eye Institute at Stanford. The study will explore how advanced imaging technologies can better detect and monitor metabolic changes in the retina, potentially identifying diseases earlier and guiding more effective treatments.
A New Frontier in Functional Eye Imaging
The study, titled “Retinal Imaging in Degeneration and Regeneration,” is led by Dr. Jeffrey Goldberg, Professor and Chair of Ophthalmology at the Byers Eye Institute. A global leader in his field, Dr. Goldberg’s research focuses on the neuroprotection and regeneration of the optic nerve—an area of critical unmet need for treating diseases like glaucoma.
“Many sight-threatening diseases progress silently, and by the time structural damage is visible, it’s often irreversible,” said Dr. Goldberg. “By incorporating functional imaging technologies like targeted ocular oximetry, we aim to detect early metabolic changes that could inform next-generation therapies—and potentially restore vision.”
Beyond Anatomy: A Functional Window into the Eye
While traditional imaging tools focus on structure, the Zilia Ocular adds a crucial functional layer by non-invasively measuring tissue oxygen saturation in targeted regions of the eye. These measurements may provide early insights into disease activity and a patient’s response to treatment, long before a patient experiences vision loss.
“Being able to quantify oxygen dynamics in the eye is a leap forward for both research and clinical care,” said Dr. Patrick Sauvageau, optometrist, CEO and Co-founder of Zilia. “We are honored to contribute to this important initiative at the Byers Eye Institute.”
About Zilia
Zilia is a health technology company developing a groundbreaking platform to non-invasively measure biomarkers in the eye, with an initial focus on ocular oximetry. By integrating advanced photonics and artificial intelligence, Zilia’s first-of-kind technology is intended to leverage the eye’s optical properties and its direct connections to the vascular system and the brain, capturing critical information on ocular and overall health.
For Further Information
Zilia: https://ziliahealth.com/
More on our Blog
Zilia Launches Clinical Study to Investigate Ocular Oximetry as a New Glaucoma Biomarker
Quebec City, July 2, 2025 – Zilia is launching a new clinical trial in collaboration with Dr. Paul...
Zilia Launches Ocular Oximetry Study for Ischemic Optic Neuropathy and Retinal Vasculitis
Quebec City, June 26, 2025 – Zilia will investigate how measuring oxygen levels in the eye could transform...
Health Canada Approves Zilia Ocular
Quebec City, 19 June 2025 - Zilia, a Canadian health technology company, is proud to announce that its...


